Burfiralimab Biosimilar – Anti-VIM mAb – Research Grade

Description of Burfiralimab Biosimilar - Anti-VIM mAb - Research Grade

Burfiralimab Biosimilar: A Novel Anti-VIM mAb for Therapeutic Targeting

Burfiralimab Biosimilar, also known as Anti-VIM mAb, is a novel monoclonal antibody (mAb) that has shown promising results in preclinical studies for its therapeutic potential. This biosimilar is a research grade antibody that specifically targets Vimentin (VIM), a protein that plays a crucial role in cell migration, invasion, and metastasis in various types of cancer.

Structure of Burfiralimab Biosimilar

Burfiralimab Biosimilar is an immunoglobulin G (IgG) type of antibody, which belongs to the class of immunoglobulins that are produced by plasma cells in response to an antigen. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain one constant domain (CL) and one variable domain (VL). The variable domains of both heavy and light chains are responsible for the specific binding to the target antigen, VIM.

Activity of Burfiralimab Biosimilar

Burfiralimab Biosimilar exerts its activity by binding to VIM, a protein that is highly expressed in cancer cells. VIM is a type III intermediate filament protein that is involved in maintaining the structural integrity of cells. In cancer cells, VIM is overexpressed, leading to increased cell motility, invasion, and metastasis. By targeting VIM, Burfiralimab Biosimilar inhibits the function of this protein, thereby reducing cancer cell migration and invasion.

Moreover, Burfiralimab Biosimilar also has an antibody-dependent cell-mediated cytotoxicity (ADCC) activity, which is a mechanism of action where the antibody binds to the target cell and activates immune cells, such as natural killer (NK) cells, to destroy the target cell. This additional activity of Burfiralimab Biosimilar makes it a potent therapeutic agent for cancer treatment.

Application of Burfiralimab Biosimilar

Burfiralimab Biosimilar has shown promising results in preclinical studies as a potential therapeutic agent for various types of cancer. In a study on breast cancer, it was found that Burfiralimab Biosimilar significantly reduced the migration and invasion of cancer cells, leading to decreased metastasis. Another study on lung cancer showed that Burfiralimab Biosimilar inhibited the growth of cancer cells and increased the survival rate in animal models.

Additionally, Burfiralimab Biosimilar has also been investigated for its potential in combination with other cancer treatments. In a study on pancreatic cancer, it was found that the combination of Burfiralimab Biosimilar with chemotherapy showed a synergistic effect in inhibiting cancer cell growth. This suggests that Burfiralimab Biosimilar may have a role in enhancing the efficacy of other cancer treatments.

Conclusion

In conclusion, Burfiralimab Biosimilar is a research grade antibody that specifically targets VIM, a protein that plays a crucial role in cancer cell migration, invasion, and metastasis. Its unique structure and activity make it a promising therapeutic agent for various types of cancer. Further studies are needed to fully understand the potential of Burfiralimab Biosimilar in cancer treatment, but its preclinical results show great potential for its future clinical applications.

Keywords: Burfiralimab Biosimilar, Anti-VIM mAb, monoclonal antibody, Vimentin, cancer, therapeutic target, structure, activity, application, preclinical studies, combination therapy